We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RICHTER:BETChemical Works of Gedeon Richter Plc Analysis

Data as of 2026-05-22 - not real-time

$40.37

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Gedeon Richter PLC trades around $40, comfortably above its 20‑day SMA (~$41) and well above the 200‑day SMA (~$32), signaling a bullish backdrop despite a bearish MACD histogram. The RSI hovers near 50, indicating neutral momentum, while volume is on an upward trend, supporting the price advance. Valuation metrics are compelling: a trailing PE of ~10 versus an industry average above 27, a near‑zero price‑to‑book ratio, and a dividend yield close to 5% with a modest 40% payout ratio suggest strong cash generation and shareholder return potential. The DCF‑derived fair value (≈$13,780) dwarfs the current market price, underscoring a deep discount that may reflect market inefficiencies rather than fundamental weakness. Recent news is limited to corporate branding events (e.g., participation at the Chessparty festival), offering no material impact on earnings or strategic outlook. Overall, the stock appears undervalued with a solid dividend, low beta, and a favorable risk‑adjusted return profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support at $38.05 but above key moving averages
  • Bearish MACD histogram suggests short‑term downside pressure
  • Increasing volume provides a cushion against abrupt drops

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap (PE ~10 vs industry ~27)
  • Robust dividend yield (~4.9%) with sustainable payout
  • Low beta (≈0.58) indicating limited market volatility exposure

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Deep discount to DCF fair value suggests upside potential
  • Stable cash flow generation and strong free cash flow
  • Strategic pipeline in women's health and CNS therapeutics

Key Metrics & Analysis

Financial Health

Revenue Growth-1.70%
Profit Margin24.80%
P/E Ratio9.9
ROE16.36%
ROA11.03%
Debt/Equity6.86
P/B Ratio0.0
Free Cash Flow$193.1B
Industry P/E27.3

Technical Analysis

TrendBullish
RSI50.3
Support$38.05
Resistance$43.99
MA 20$41.31
MA 50$38.01
MA 200$31.89
MACDBearish
VolumeIncreasing
Fear & Greed Index91.16

Valuation

Fair Value$13,780.10
GradeUndervalued
TypeValue
Dividend Yield4.87%

Risk Assessment

Beta0.58
Volatility58.22%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.